Batavia Biosciences

The International AIDS Vaccine Initiative (IAVI) has entered another agreement to use Batavia Biosciences’ novel HIP-Vax platform to manufacture doses for clinical trials, the Dutch CDMO announced last week. This time around, the vaccine candidate is IAVI’s Sudan ebolavirus shot.

Batavia is already using the high-volume, low-cost, small-footprint technology to produce doses for Phase 1 trials of IAVI’s Lassa fever vaccine candidate. Both candidates use a recombinant vesicular…

Batavia Biosciences announced last week that it has successfully manufactured shots for Phase 1 trials in Africa and the U.S. of the recombinant vesicular stomatitis virus (rVSV) vector-based Lassa fever vaccine being developed by the International AIDS Vaccine Initiative (IAVI).

The Dutch company, which initially partnered with IAVI in 2018, said it manufactured rVSVΔG-LASV-GPC using its HIP-Vax platform, which “enables the production of high volumes of vaccine doses in a small…

The state of the hunt:

The United Kingdom issued emergency authorization of Pfizer/BioNTech’s vaccine.
  WHO is reviewing the Pfizer/BioNTech shot for Emergency Use Listing.
  Moderna requested emergency nods for its mRNA-based vaccine from the U.S. FDA and the European Medicines Agency.

 

Vaccines


Approved or authorized vaccines

Pfizer is now seeking full British marketing authorization for its Covid-19 vaccine “in parallel” with the…

Batavia Biosciences and Valneva announced this week that they would work together to “accelerate market access” to a low-cost inactivated polio vaccine (IPV), according to a joint press release.

For an undisclosed upfront payment and monthly service fees, Valneva’s Swedish subsidiary will manufacture Sabin-based IPV using Batavia's low-cost HIP-VAX manufacturing process in combination with Univercells' NevoLine micro-facility technology. France’s Batavia will supply the…

Batavia Biosciences announced this week that the Gates Foundation is investing an additional $13.2 million to help the Dutch company advance low-cost polio vaccine manufacturing.

Batavia said the funds will enable it to use its optimized process and consortium partner Univercells’ NevoLine micro-facility platform to supply clinical-grade Sabin-based inactivated polio vaccine to developing country manufacturers and accelerate licensing of new vaccine products at less than $0.30 per dose…